Your browser doesn't support javascript.
loading
Effect of intermittent preventive treatment for malaria with dihydroartemisinin-piperaquine on immune responses to vaccines among rural Ugandan adolescents: randomised controlled trial protocol B for the 'POPulation differences in VACcine responses' (POPVAC) programme.
Natukunda, Agnes; Nkurunungi, Gyaviira; Zirimenya, Ludoviko; Nassuuna, Jacent; Oduru, Gloria; Amongin, Rebecca; Kabuubi, Prossy N; Mutebe, Alex; Onen, Caroline; Amongi, Susan; Nakazibwe, Esther; Akello, Florence; Kiwanuka, Samuel; Kiwudhu, Fred; Sewankambo, Moses; Nsubuga, Denis; Kizindo, Robert; Staedke, Sarah G; Cose, Stephen; Webb, Emily; Elliott, Alison M.
Afiliación
  • Natukunda A; Immunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Nkurunungi G; Immunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda Gyaviira.Nkurunungi@mrcuganda.org.
  • Zirimenya L; Immunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Nassuuna J; Immunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Oduru G; Immunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Amongin R; Immunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Kabuubi PN; Immunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Mutebe A; Immunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Onen C; Immunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Amongi S; Immunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Nakazibwe E; Immunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Akello F; Immunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Kiwanuka S; Immunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Kiwudhu F; Immunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Sewankambo M; Immunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Nsubuga D; Immunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Kizindo R; Immunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Staedke SG; Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.
  • Cose S; Infectious Diseases Research Collaboration, Kampala, Uganda.
  • Webb E; Immunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
  • Elliott AM; Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK.
BMJ Open ; 11(2): e040427, 2021 02 16.
Article en En | MEDLINE | ID: mdl-33593769
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Malaria / Antimaláricos Tipo de estudio: Clinical_trials / Guideline / Risk_factors_studies País/Región como asunto: Africa Idioma: En Revista: BMJ Open Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Malaria / Antimaláricos Tipo de estudio: Clinical_trials / Guideline / Risk_factors_studies País/Región como asunto: Africa Idioma: En Revista: BMJ Open Año: 2021 Tipo del documento: Article